Who Paid My Doc
Open-Label, Multicenter Phase 1/2 Study of Mogamulizumab in Combination with Nivolumab in Subjects with Locally Advanced or Metastatic Solid Tumors
Research payments
$433,043
Through program year 2020, $433,043 in research payments was reported against Open-Label, Multicenter Phase 1/2 Study of Mogamulizumab in Combination with Nivolumab in Subjects with Locally Advanced or Metastatic Solid Tumors, across 4 payments, paid by Kyowa Kirin Pharmaceutical Development, Inc.
- Paid by
- Kyowa Kirin Pharmaceutical Development, Inc
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
1 row| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2020 | Research | $433,043 | 4 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
2 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.